

16387 U.S.PTO  
03160422390 U.S.PTO  
10/801985

031604

## CERTIFICATE OF EXPRESS MAIL

NUMBER EV 326410916 US

DATE OF DEPOSIT March 16, 2004

## PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Dkt. No.: MYOG:034US

Prior Application Examiner:  
**RAYMOND J. HENLEY, III**

## BOX PATENT APPLICATION

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

## Classification Designation:

**Prior Group Art Unit: 1614**

**REQUEST FOR FILING CONTINUATION APPLICATION  
UNDER 37 C.F.R. § 1.53(b)**

This is a request for filing a continuation application under Rule 53(b) (37 C.F.R. § 1.53(b)) of co-pending prior application Serial No. 10/256,221 filed September 26, 2002, entitled "INHIBITION OF HISTONE DEACETYLASE AS A TREATMENT FOR CARDIAC HYPERTROPHY."

1. Enclosed is a copy of the prior application Serial No. 10/256,221 as originally filed, including specification, claims, drawings, and declaration. The undersigned hereby verifies that the attached papers are a true copy of the prior application as originally filed and identified above, that no amendments (if any) referred to in the declaration filed to complete the prior application introduced new matter therein, and further that this statement was made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or

both, under Section 1001 of Title 18 of the United States Code, and that such willful false statement may jeopardize the validity of the application or any patent issuing thereon.

(a)  The inventorship is the same as prior Application Serial No. 10/256,221.

(b)  Deletion of inventor(s). Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. § 1.63(d)(2) and 1.33(b).

(c)  Priority of foreign patent application number , filed in is claimed under 35 U.S.C. § 119(a)-(e). The certified copy:  
 is enclosed.  
 has been filed in the prior Application Serial No.

2. The Commissioner is requested to grant Applicants a filing date in accordance with Rule 1.53, and supply Applicants with a Notice of Missing Parts in due course, in accordance with the provisions of Rule 1.53(f).
3. Enclosed is a check in the amount of \$ to cover the filing fee as calculated below and the fee for any new claims added in the Preliminary Amendment referred to in Part No. 9 below.

CLAIMS AS FILED IN THE PRIOR APPLICATION  
LESS CLAIMS CANCELED BELOW

FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
Basic Fee -----				\$740 .00
Total Claims	- 20 =	X	\$18.00 =	\$ .00
Independent Claims	- 3 =	X	\$84.00 =	\$ .00
Multiple Dependent Claim(s) -----				\$-0-.00

FOR	NUMBER FILED	TOTAL FILING FEES:		\$ .00 FEE
		NUMBER EXTRA	RATE	

- 4. Applicant is entitled to Small Entity Status for this application.
- (a) A small entity statement is enclosed.
- (b) A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
- (c) Small entity status is no longer claimed.
- 5. If the check is missing or insufficient, the Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 to 1.21 which may be required for any reason relating to this application, or credit any overpayment to Fulbright & Jaworski L.L.P. Account No.: 50-1212/
- 6. Enclosed is a copy of the current Power of Attorney in the prior application.
- 7. Address all future communications to:


Steven L. Highlander, Esq.  
 FULBRIGHT & JAWORSKI L.L.P.  
 600 Congress Avenue, Suite 2400  
 Austin, Texas 78701  
 (512) 536-3184

- 8. The prior application is presently assigned to Regents of the University of Colorado, A body Corporate, The and Board of Regents, The University of Texas System.
- 9. Enclosed is a preliminary amendment. Any additional fees incurred by this amendment are included in the check at No. 3 above and said fee has been calculated after calculation of claims and after amendment of claims by the preliminary amendment.
- 10. Cancel in this application claims \_\_\_\_\_ of the prior application before calculating the filing fee. (At least one original independent claim must be retained).
- 11. Amend the specification by inserting before the first line the sentence: --This is a continuation of co-pending application Serial No. 10/256,221 filed September 26, 2002--.
- 12. Enclosed are formal drawings.
- 13. An Information Disclosure Statement (IDS) is enclosed.
  - (a) PTO-1449.
  - (b) Copies of IDS citations.
- 14. Transfer the sequence information, including the computer readable form previously submitted in the parent application, Serial No. 10/256,221 filed September 26, 2002, for use in this application. **Under 37 C.F.R. § 1.821(e),** Applicants state that the paper copy of the sequence listing in this application is identical to the computer readable copy in parent application Serial No. 10/256,221 filed September 26, 2002. **Under 37 C.F.R. § 1.821(f),** Applicants also state that the

**information recorded in computer readable form is identical to the written sequence listing.**

- 15. Other: Request for Transfer of Sequence Listing Under 37 C.F.R. § 1.821(f).
- 16. Return Receipt Postcard (should be specifically itemized).

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 536-3184

Date: March 16, 2004